VIDEO: TL1A inhibitors’ ‘unique mechanism of action’ may reshape IBD care

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ligand 1A inhibitors in treating inflammatory bowel disease.

In a Healio video exclusive, Edward V. Loftus Jr., MD , discusses the potential of tumor necrosis factor-like ligand 1A inhibitors in treating inflammatory bowel disease.

This class of drugs has shown early promise in both Crohn’s disease and ulcerative colitis.

“This is an interesting mechanism of action because not only is it involved in inflammation, but it may also be involved in the development of fibrosis,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at Mayo Clinic and chief medical editor of Healio Gastroenterology, said. “It holds out the possibility that maybe some symptomati